MeiraGTx's AAV-hAQP1 Shows Sustained Efficacy in Xerostomia Trial
Event summary
- MeiraGTx reported positive three-year data from its Phase 1 AQUAx study of AAV-hAQP1 for treating grade 2/3 late radiation-induced xerostomia.
- Clinically meaningful improvements in xerostomia symptoms and unstimulated whole saliva flow rate were maintained out to 3 years post-treatment.
- AAV-hAQP1 was safe and well-tolerated at each dose tested.
- The Phase 1 AQUAx trial is an open-label, non-randomized, dose escalation study with a primary endpoint of safety.
The big picture
MeiraGTx's positive three-year data for AAV-hAQP1 underscores the potential of gene therapy in treating chronic conditions with no existing therapies. The durability of the treatment's effects could set a new benchmark for gene therapy efficacy, particularly in areas with high unmet medical needs. This development comes at a time when the biotech industry is increasingly focused on leveraging genetic medicines to address severe, debilitating diseases.
What we're watching
- Regulatory Pathway
- Whether the sustained efficacy data will accelerate regulatory approval for AAV-hAQP1.
- Commercial Potential
- The pace at which MeiraGTx can translate these results into a commercially viable treatment option.
- Competitive Landscape
- How this data positions AAV-hAQP1 against other potential treatments for radiation-induced xerostomia.
Related topics